Drug Profile
ZYN 001
Alternative Names: D-glyceric acid ester delta 9-tetrahydrocannabinol; Tetrahydrocannabinol prodrug; Tetrahydrocannabinol prodrug transdermal patch; THC prodrug; THC prodrug transdermal patch; ZYN-001Latest Information Update: 13 Oct 2023
Price :
$50
*
At a glance
- Originator Zynerba Pharmaceuticals
- Class Antiemetics; Cannabinoids; Esters; Neuroprotectants; Non-opioid analgesics; Sugar acids
- Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer pain; Fibromyalgia; Neuropathic pain
Most Recent Events
- 11 Oct 2023 Zynerba Pharmaceuticals has been acquired by Harmony Biosciences
- 02 May 2023 Discontinued - Preclinical for Cancer pain in USA (Transdermal)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Cancer-pain in USA (Transdermal, Patch)